Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by The Oncology Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Oncology Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

S3 E3 The Oncology Journal Club Podcast: To INFINITY and Beyond! Rethinking Treatment Paradigms and Common Sense Trial Design

35:08
 
Share
 

Manage episode 478561267 series 2865758
Content provided by The Oncology Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Oncology Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Send us a text

Welcome to The Oncology Journal Club Podcast Series 3
Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology Network
The Oncology Journal Club team take a deep dive into three standout papers:

  • Craig kicks us off with a timely perspective on the long-term toxicity of immune checkpoint inhibitors—are we ready to widen the lens? He highlights the need for more comprehensive research on survivorship issues including quality of life, financial impact and psychological outcomes.
  • Kate brings us the exciting results from the INFINITY study on gastric and gastroesophageal cancers which shows impressive complete response rates in dMMR gastric cancers but at prohibitive costs — and poses a big question: are we ready to rethink treatment paradigms?
  • And CJ unpacks the Common Sense Oncology principles for designing better phase 3 trials — Common Sense Oncology principles offer a patient-centred framework for designing and reporting clinical trials.
  • Of course, we’ve also got our Quick Bites—those quirky, surprising papers that made us raise an eyebrow or two. From RNA vaccines in pancreatic cancer to updated ASCO guidelines for small cell lung cancer, it’s a rapid-fire segment you won’t want to miss.

For links to the papers discussed and bios of our hosts, head to the show notes on oncologynetwork.com.au.
Subscribe to The Oncology Newsletter for regular updates on the latest cancer research and join our community at oncologynetwork.com.au.
The Oncology Podcast - An Australian Oncology Perspective

  continue reading

Chapters

1. S3 E3 The Oncology Journal Club Podcast: To INFINITY and Beyond! Rethinking Treatment Paradigms and Common Sense Trial Design (00:00:00)

2. Welcome to Oncology Journal Club (00:00:04)

3. Long-term Toxicity of Immune Checkpoint Inhibitors (00:01:34)

4. INFINITY Study: Gastric Cancer Breakthroughs (00:02:42)

5. Common Sense Principles for Clinical Trials (00:08:00)

6. RFA vs SBRT for Hepatocellular Carcinoma (00:16:42)

7. mRNA Vaccines in Pancreatic Cancer (00:22:26)

8. Key Guideline Updates and Cancer Statistics (00:27:36)

146 episodes

Artwork
iconShare
 
Manage episode 478561267 series 2865758
Content provided by The Oncology Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Oncology Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Send us a text

Welcome to The Oncology Journal Club Podcast Series 3
Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology Network
The Oncology Journal Club team take a deep dive into three standout papers:

  • Craig kicks us off with a timely perspective on the long-term toxicity of immune checkpoint inhibitors—are we ready to widen the lens? He highlights the need for more comprehensive research on survivorship issues including quality of life, financial impact and psychological outcomes.
  • Kate brings us the exciting results from the INFINITY study on gastric and gastroesophageal cancers which shows impressive complete response rates in dMMR gastric cancers but at prohibitive costs — and poses a big question: are we ready to rethink treatment paradigms?
  • And CJ unpacks the Common Sense Oncology principles for designing better phase 3 trials — Common Sense Oncology principles offer a patient-centred framework for designing and reporting clinical trials.
  • Of course, we’ve also got our Quick Bites—those quirky, surprising papers that made us raise an eyebrow or two. From RNA vaccines in pancreatic cancer to updated ASCO guidelines for small cell lung cancer, it’s a rapid-fire segment you won’t want to miss.

For links to the papers discussed and bios of our hosts, head to the show notes on oncologynetwork.com.au.
Subscribe to The Oncology Newsletter for regular updates on the latest cancer research and join our community at oncologynetwork.com.au.
The Oncology Podcast - An Australian Oncology Perspective

  continue reading

Chapters

1. S3 E3 The Oncology Journal Club Podcast: To INFINITY and Beyond! Rethinking Treatment Paradigms and Common Sense Trial Design (00:00:00)

2. Welcome to Oncology Journal Club (00:00:04)

3. Long-term Toxicity of Immune Checkpoint Inhibitors (00:01:34)

4. INFINITY Study: Gastric Cancer Breakthroughs (00:02:42)

5. Common Sense Principles for Clinical Trials (00:08:00)

6. RFA vs SBRT for Hepatocellular Carcinoma (00:16:42)

7. mRNA Vaccines in Pancreatic Cancer (00:22:26)

8. Key Guideline Updates and Cancer Statistics (00:27:36)

146 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play